Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles

J Control Release. 2016 Mar 10:225:230-9. doi: 10.1016/j.jconrel.2016.01.050. Epub 2016 Jan 28.

Abstract

In this study, we used cationic lipid-poly(lactide-co-glycolide) acid (PLGA) hybrid nanoparticles as antigen delivery carriers to investigate how antigen-loading methods affect antigen exposure to the immune system and evaluated the resulting antigen-specific immune responses. We formulated three classes of antigen adsorbed and/or encapsulated cationic lipid-PLGA hybrid nanoparticles; we designated antigen-adsorbed (out), antigen-encapsulated (in), and antigen-adsorbed/encapsulated (both) nanoparticles. Our results demonstrate significantly more efficient lysosomal escape and cross-presentation of antigen from dendritic cells (DCs) that were exposed to "both" and "in" nanoparticles. In vivo experiments further revealed that "both" nanoparticles significantly more effectively provided not only adequate initial antigen exposure but also long-term antigen persistence at the injection site. Data from flow cytometry and ELISA analyses demonstrated elevated in vivo immune responses from mice that were immunized with nanoparticles-delivered OVA when compared with free OVA. In addition, "in" and "both" nanoparticles elicited significantly higher antigen-specific immune response than "out" nanoparticles and free OVA. These results suggest that the location of antigen entrapment is an important factor in modulating the immune responses of antigens delivered by nanoparticles. Overall, we propose here a promising approach for the future design of vaccines using cationic lipid-PLGA nanoparticles.

Keywords: Adjuvant; Adsorption; Cationic-lipid PLGA hybrid nanoparticles; Encapsulation; Immune response; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adsorption
  • Animals
  • Antigens / administration & dosage*
  • Antigens / chemistry
  • Antigens / pharmacology
  • B7-2 Antigen / immunology
  • Biological Transport
  • Cholesterol / administration & dosage
  • Cholesterol / analogs & derivatives*
  • Cholesterol / chemistry
  • Cholesterol / pharmacology
  • Dendritic Cells / immunology
  • Female
  • Immunoglobulin G / blood
  • Interferon-gamma / immunology
  • Interleukin-4 / immunology
  • Lactic Acid / administration & dosage*
  • Lactic Acid / chemistry
  • Lactic Acid / pharmacology
  • Lymph Nodes / cytology
  • Major Histocompatibility Complex / immunology
  • Mice, Inbred C57BL
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Ovalbumin / administration & dosage*
  • Ovalbumin / chemistry
  • Ovalbumin / pharmacology
  • Polyglycolic Acid / administration & dosage*
  • Polyglycolic Acid / chemistry
  • Polyglycolic Acid / pharmacology
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Spleen / cytology
  • Vaccines / administration & dosage*
  • Vaccines / chemistry

Substances

  • Antigens
  • B7-2 Antigen
  • Immunoglobulin G
  • Vaccines
  • 3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Interleukin-4
  • Polyglycolic Acid
  • Lactic Acid
  • Interferon-gamma
  • Ovalbumin
  • Cholesterol